According to Dr Neha, fibroid therapies such as GnRH agonists or SPRMs undergo hepatic metabolism, occasionally elevating liver enzymes or inducing drug-related hepatotoxicity. Routine monitoring of ALT, AST, and bilirubin levels ensures early detection. Drug cessation generally reverses mild hepatic injury, though fibrosis or cirrhosis may show limited recovery despite treatment modification.